696P - Ten weeks to live: A population-based study on treatment and survival of patients with metastatic pancreatic cancer in the south of the Netherlands

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anticancer Agents
Pancreatic Cancer
Biological Therapy
Presenter Nienke Bernards
Citation Annals of Oncology (2014) 25 (suppl_4): iv210-iv253. 10.1093/annonc/mdu334
Authors N. Bernards1, N. Haj Mohammad2, G. Creemers3, I.H.J.T. De Hingh4, H. van Laarhoven2, V. Lemmens1
  • 1Dutch Cancer Registry, Comprehensive cancer center Netherlands, 5600AE - Eindhoven/NL
  • 2Medical Oncology, Academic Medical Center, 1100DD - Amsterdam/NL
  • 3Department Of Internal Medicine, Catharina Hospital Eindhoven, NL-5602 ZA - Eindhoven/NL
  • 4Department Of Surgery, Catharina Hospital Eindhoven, NL-5602 ZA - Eindhoven/NL



The aim of this study was to investigate trends in treatment and survival of patients with metastatic pancreatic cancer.


All patients diagnosed with pancreatic cancer between 1993 and 2010 in the South of the Netherlands were included (N= 3,099). Crude overall survival was analyzed and independent risk factors for death were identified.


The proportion of patients presenting with metastatic disease increased during the study period (35% in 1993-1996 vs. 59% in 2009-2010, P < 0.0001). Overall, 18% of these patients were treated with chemotherapy. Prescription of chemotherapy almost tripled (10% in 1993-1996 versus 27% in 2009-2010, P < 0.0001). Treatment largely depended on age, ranging from 38% among patients aged <50 years (<50 yrs vs. 60-69 yrs: adjusted odds ratio (ORadj) 2.5, P = 0.001) to 1% among patients aged 80 years or older (80+ yrs vs. 60-69 yrs: ORadj 0.04, P < 0.0001). Patients were more likely to receive chemotherapy if they were of high socioeconomic status (ORadj 2.0, P = 0.001), and if diagnosis was pathologically confirmed (no pathologic verification vs. pathologic verification: ORadj 0.3, P < 0.0001). Administration of chemotherapy varied widely between ten community hospitals (5-34%, P < 0.0001). Median overall survival of patients with metastatic pancreatic cancer remained 9-11 weeks throughout the study period.


A growing proportion of pancreatic cancer patients presented with metastatic disease. Usage of palliative chemotherapy increased over time, but median survival remained 9-11 weeks. In the near future, it should be evaluated to what degree the recently introduced combination treatment regimens have had an impact on population-based survival.


All authors have declared no conflicts of interest.